Page last updated: 2024-10-21

tacrine and Parkinson Disease, Secondary

tacrine has been researched along with Parkinson Disease, Secondary in 5 studies

Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research Excerpts

ExcerptRelevanceReference
") proved capable of reducing jaw tremors in tacrine model of Parkinson's disease tremor."3.74Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. ( Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E, 2007)
"Tacrine-treated rats showed a slight increase in the average initiation time for fast responses (i."1.30Motor dysfunction produced by tacrine administration in rats. ( Aberman, J; Carriero, DL; Gianutsos, G; Mayorga, AJ; Outslay, G; Salamone, JD, 1997)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tronci, E1
Simola, N1
Borsini, F1
Schintu, N1
Frau, L1
Carminati, P1
Morelli, M1
McSwain, ML1
Forman, LM1
Maany, I1
Carriero, DL1
Outslay, G1
Mayorga, AJ1
Aberman, J1
Gianutsos, G1
Salamone, JD1
Cabeza-Alvarez, CI1
González-Rubio, M1
García-Montero, R1
Alvarez-Tejerina, A1

Other Studies

5 other studies available for tacrine and Parkinson Disease, Secondary

ArticleYear
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    European journal of pharmacology, 2007, Jul-02, Volume: 566, Issue:1-3

    Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavi

2007
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
    Journal of clinical psychopharmacology, 1995, Volume: 15, Issue:4

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Drug Therapy, Combination; Haloperidol; Hum

1995
Adverse interaction of tacrine and haloperidol.
    The American journal of psychiatry, 1996, Volume: 153, Issue:11

    Topics: Aged; Dementia; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Humans; Parkinson

1996
Motor dysfunction produced by tacrine administration in rats.
    Pharmacology, biochemistry, and behavior, 1997, Volume: 58, Issue:4

    Topics: Animals; Cholinesterase Inhibitors; Conditioning, Operant; Dose-Response Relationship, Drug; Dyskine

1997
[Parkinsonian syndrome related to tacrine].
    Neurologia (Barcelona, Spain), 1999, Volume: 14, Issue:2

    Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Humans; Male; Parkinson Disease, Secon

1999